<DOC>
	<DOCNO>NCT01143077</DOCNO>
	<brief_summary>Lurasidone ( lurasidone HCl ) novel psychotropic agent develop potential new antipsychotic treatment patient schizophrenia . Switching antipsychotic medication common treatment schizophrenia . The current study design evaluate effectiveness , safety , tolerability switch clinically stable , symptomatic outpatient schizophrenia schizoaffective disorder preswitch antipsychotic medication lurasidone , period 6 week .</brief_summary>
	<brief_title>A Study Evaluating Lurasidone The Treatment Schizophrenia Schizoaffective Disorder Subjects Switched From Other Antipsychotic Agents</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Subject â‰¥ 18 year age . Subject meet DSMIV criterion primary diagnosis schizophrenia schizoaffective disorder . Subject must judge investigator appropriate candidate switch current antipsychotic medication due insufficient efficacy and/or safety tolerability concern . Presence Axis I Axis II disorder schizophrenia schizoaffective disorder primary focus treatment prior screen . Subject experience persistent lack improvement psychotic symptom despite adequate trial ( least 6 week standard dos ) , two antipsychotic agent 12 month prior screen . Subject consider investigator imminent risk suicide harm self , others , property . Subject suicidal ideation baseline attempt suicide within 90 day prior randomization ( even without hospitalization ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Lurasidone</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Latuda</keyword>
</DOC>